Duke University
The Global Health Discovery Collaboratory Antibody Dynamics team at Duke University Center for Human Systems Immunology is seeking a detail-oriented scientist to support antibody biophysical measurements in an immune monitoring core lab. The role involves performing experiments to measure biomolecular interactions using Surface Plasmon Resonance (SPR) and Bio-layer interferometry (BLI) for vaccine trials targeting global diseases. The position requires managing and analyzing data sets while collaborating with program managers and statistical teams to ensure quality control.
Duke University is a private research university in Durham, North Carolina, offering rigorous undergraduate, graduate, and professional programs. It houses prominent schools of medicine, nursing, engineering, law, business, and public policy alongside Duke Health and multiple research institutes that translate discovery into clinical care and industry partnerships. Duke emphasizes interdisciplinary scholarship, global engagement, and innovation across the sciences, arts, and humanities, attracting selective students and faculty from around the world. Its Research Triangle location fosters collaboration with nearby universities, hospitals, and technology companies.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Duke University.
27% below the average for this role
Protein Analytics Team Member
Xaira Therapeutics
Principal Scientist – SPR and Biophysical Assays
UCB
Principal Scientist – SPR and Biophysical Assays
UCB
Senior Scientist - Surface Plasmon Resonance (SPR) and Characterization
IQVIA
Associate Scientist-Biomolecular Interactions
Regeneron Pharmaceuticals
Scientist I, Biochemistry and Biotherapeutics
PharmaEssentia